Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 309

1.

Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations.

Maritan M, Ambrosetti A, Oberti L, Barbiroli A, Diomede L, Romeo M, Lavatelli F, Sormanni P, Palladini G, Bolognesi M, Merlini G, Ricagno S.

Amyloid. 2019;26(sup1):105-106. doi: 10.1080/13506129.2019.1583185. No abstract available.

PMID:
31343361
2.

The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis.

Oberti L, Maritan M, Rognoni P, Barbiroli A, Lavatelli F, Russo R, Palladini G, Bolognesi M, Merlini G, Ricagno S.

Amyloid. 2019;26(sup1):107-108. doi: 10.1080/13506129.2019.1583187. No abstract available.

PMID:
31343357
3.

Predicting survival in light chain amyloidosis.

Palladini G, Milani P, Merlini G.

Haematologica. 2019 Jul;104(7):1294-1296. doi: 10.3324/haematol.2019.218859. No abstract available.

4.

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients.

Tasaki M, Milani P, Foli A, Verga L, Obici L, Basset M, Bozzola M, Ferraro G, Nuvolone M, Morbini P, Capello G, Ueda M, Obayashi K, Paulli M, Ando Y, Merlini G, Palladini G, Lavatelli F.

Blood. 2019 Jul 18;134(3):320-323. doi: 10.1182/blood.2019000420. Epub 2019 Jun 6. No abstract available.

PMID:
31171502
5.

Parkinsonism and dysautonomia: Multiple system atrophy?

Albanese A, Cocco A, Milani P, Lalli S, Palladini G.

Parkinsonism Relat Disord. 2019 May 3. pii: S1353-8020(19)30226-3. doi: 10.1016/j.parkreldis.2019.05.005. [Epub ahead of print] No abstract available.

PMID:
31097298
6.

Fatty Acid Desaturase Involvement in Non-Alcoholic Fatty Liver Disease Rat Models: Oxidative Stress Versus Metalloproteinases.

Palladini G, Di Pasqua LG, Berardo C, Siciliano V, Richelmi P, Mannucci B, Croce AC, Rizzo V, Perlini S, Vairetti M, Ferrigno A.

Nutrients. 2019 Apr 8;11(4). pii: E799. doi: 10.3390/nu11040799.

7.

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.

Swuec P, Lavatelli F, Tasaki M, Paissoni C, Rognoni P, Maritan M, Brambilla F, Milani P, Mauri P, Camilloni C, Palladini G, Merlini G, Ricagno S, Bolognesi M.

Nat Commun. 2019 Mar 20;10(1):1269. doi: 10.1038/s41467-019-09133-w.

8.

Animal Models of Steatosis (NAFLD) and Steatohepatitis (NASH) Exhibit Hepatic Lobe-Specific Gelatinases Activity and Oxidative Stress.

Palladini G, Di Pasqua LG, Berardo C, Siciliano V, Richelmi P, Perlini S, Ferrigno A, Vairetti M.

Can J Gastroenterol Hepatol. 2019 Feb 3;2019:5413461. doi: 10.1155/2019/5413461. eCollection 2019.

9.

ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis.

Ami D, Mereghetti P, Foli A, Tasaki M, Milani P, Nuvolone M, Palladini G, Merlini G, Lavatelli F, Natalello A.

Anal Chem. 2019 Feb 19;91(4):2894-2900. doi: 10.1021/acs.analchem.8b05008. Epub 2019 Feb 4.

PMID:
30676723
10.

When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression.

Palladini G, Merlini G.

Blood Adv. 2019 Jan 22;3(2):212-215. doi: 10.1182/bloodadvances.2018021253. No abstract available.

11.

A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options.

Moutafi M, Ziogas DC, Michopoulos S, Bagratuni T, Vasileiou V, Verga L, Merlini G, Palladini G, Matsouka C, Dimopoulos MA, Kastritis E.

BMC Med Genet. 2019 Jan 21;20(1):23. doi: 10.1186/s12881-019-0755-5.

12.

Systemic immunoglobulin light chain amyloidosis.

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA.

Nat Rev Dis Primers. 2018 Oct 25;4(1):38. doi: 10.1038/s41572-018-0034-3. Review.

PMID:
30361521
13.

Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

Milani P, Schönland S, Merlini G, Kimmich C, Foli A, Dittrich T, Basset M, Müller-Tidow C, Bochtler T, Palladini G, Hegenbart U.

Blood. 2018 Nov 1;132(18):1988-1991. doi: 10.1182/blood-2018-04-845396. Epub 2018 Aug 14. No abstract available.

PMID:
30108065
14.

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.

Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, Toskic D, Jaccard A, Hansen T, Bladé J, Cibeira MT, Kastritis E, Dispenzieri A, Wechalekar A, Varga C, Schönland SO, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e493-e499. doi: 10.1016/j.clml.2018.07.292. Epub 2018 Jul 25.

15.

Novel Therapies in Light Chain Amyloidosis.

Milani P, Merlini G, Palladini G.

Kidney Int Rep. 2017 Nov 28;3(3):530-541. doi: 10.1016/j.ekir.2017.11.017. eCollection 2018 May. Review.

16.

Management of the elderly patient with AL amyloidosis.

Nuvolone M, Milani P, Palladini G, Merlini G.

Eur J Intern Med. 2018 Dec;58:48-56. doi: 10.1016/j.ejim.2018.05.004. Epub 2018 May 23. Review.

PMID:
29801808
17.

Light Chain Amyloidosis.

Milani P, Merlini G, Palladini G.

Mediterr J Hematol Infect Dis. 2018 Mar 1;10(1):e2018022. doi: 10.4084/MJHID.2018.022. eCollection 2018. Review.

18.

The elusive pathogenesis of Schnitzler syndrome.

Palladini G, Merlini G.

Blood. 2018 Mar 1;131(9):944-946. doi: 10.1182/blood-2018-01-824862. No abstract available.

19.

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.

Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, Russo F, Psimenou E, Apostolakou F, Roussou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas DC, Papadopoulou E, Pamboucas C, Dimopoulos MA, Palladini G.

Blood. 2018 Apr 5;131(14):1568-1575. doi: 10.1182/blood-2017-12-819904. Epub 2018 Jan 31.

20.

New concepts in the treatment and diagnosis of amyloidosis.

Milani P, Palladini G, Merlini G.

Expert Rev Hematol. 2018 Feb;11(2):117-127. doi: 10.1080/17474086.2018.1424534. Epub 2018 Jan 10. Review.

PMID:
29307226
21.

Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.

Oberti L, Rognoni P, Barbiroli A, Lavatelli F, Russo R, Maritan M, Palladini G, Bolognesi M, Merlini G, Ricagno S.

Sci Rep. 2017 Dec 1;7(1):16809. doi: 10.1038/s41598-017-16953-7.

22.

Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.

Imperlini E, Gnecchi M, Rognoni P, Sabidò E, Ciuffreda MC, Palladini G, Espadas G, Mancuso FM, Bozzola M, Malpasso G, Valentini V, Palladini G, Orrù S, Ferraro G, Milani P, Perlini S, Salvatore F, Merlini G, Lavatelli F.

Sci Rep. 2017 Nov 15;7(1):15661. doi: 10.1038/s41598-017-15424-3.

23.

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.

Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G.

Blood. 2018 Feb 1;131(5):525-532. doi: 10.1182/blood-2017-04-780544. Epub 2017 Nov 3.

24.

The lung in amyloidosis.

Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G.

Eur Respir Rev. 2017 Sep 6;26(145). pii: 170046. doi: 10.1183/16000617.0046-2017. Print 2017 Sep 30. Review.

25.

Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Meziane I, Huhn S, Filho MIDS, Weinhold N, Campo C, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Jauch A, Morgan GJ, Houlston R, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Försti A, Schönland SO, Hemminki K.

Haematologica. 2017 Oct;102(10):e411-e414. doi: 10.3324/haematol.2017.171108. Epub 2017 Jul 4. No abstract available.

26.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.

27.

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G.

Blood. 2017 Aug 3;130(5):625-631. doi: 10.1182/blood-2017-02-767467. Epub 2017 May 25.

28.

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Milani P, Basset M, Russo F, Foli A, Lavatelli F, Nuvolone M, Ferraro G, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):64-65. doi: 10.1080/13506129.2017.1293517. No abstract available.

PMID:
28434343
29.

Patterns of relapse after upfront bortezomib therapy in AL amyloidosis.

Basset M, Milani P, Russo F, Lavatelli F, Nuvolone M, Foli A, Perlini S, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):60-61. doi: 10.1080/13506129.2017.1292901. No abstract available.

PMID:
28434342
30.

Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis.

Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Merlini G.

Amyloid. 2017 Mar;24(sup1):68-69. doi: 10.1080/13506129.2017.1293644. No abstract available.

PMID:
28434326
31.

Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.

Russo F, Valentini V, Basset M, Bosoni T, Milani P, Ferraro G, Pirolini L, Foli A, Lavatelli F, Belvisi F, Consogno G, Nuvolone M, Li Bergolis F, Bozzola M, Albertini R, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):66-67. doi: 10.1080/13506129.2017.1293643. No abstract available.

PMID:
28434323
32.

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.

Milani P, Schönland S, Palladini G, Kimmich C, Basset M, Russo F, Foli A, Perlini S, Bochtler T, Ho AD, Merlini G, Hegenbart U.

Amyloid. 2017 Mar;24(sup1):56-57. doi: 10.1080/13506129.2017.1292240. No abstract available.

PMID:
28434298
33.

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.

Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Perlini S, Merlini G.

Amyloid. 2017 Mar;24(sup1):54-55. doi: 10.1080/13506129.2017.1289916. No abstract available.

PMID:
28434293
34.

Prognostication of survival and progression to dialysis in AA amyloidosis.

Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, Foli A, Lavatelli F, Nuvolone M, Casarini S, Obici L, Merlini G.

Amyloid. 2017 Mar;24(sup1):136-137. doi: 10.1080/13506129.2017.1289917. No abstract available.

PMID:
28434292
35.

Regulated expression of amyloidogenic immunoglobulin light chains in mice.

Nuvolone M, Sorce S, Pelczar P, Rushing E, Lavatelli F, Rognoni P, Valentini V, Palladini G, Merlini G, Aguzzi A.

Amyloid. 2017 Mar;24(sup1):52-53. doi: 10.1080/13506129.2017.1289914. No abstract available.

PMID:
28434289
36.

Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.

Palladini G, Jaccard A, Milani P, Lavergne D, Foli A, Bender S, Lavatelli F, Bosoni T, Valentini V, Pirolini L, Ferraro G, Basset M, Russo F, Nuvolone M, Albertini R, Cogne M, Merlini G.

Clin Chem Lab Med. 2017 Oct 26;55(11):1734-1743. doi: 10.1515/cclm-2016-1024.

PMID:
28343171
37.

Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage.

Diomede L, Romeo M, Rognoni P, Beeg M, Foray C, Ghibaudi E, Palladini G, Cherny RA, Verga L, Capello GL, Perfetti V, Fiordaliso F, Merlini G, Salmona M.

Antioxid Redox Signal. 2017 Sep 20;27(9):567-582. doi: 10.1089/ars.2016.6848. Epub 2017 Mar 3.

38.

The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.

Oliva L, Orfanelli U, Resnati M, Raimondi A, Orsi A, Milan E, Palladini G, Milani P, Cerruti F, Cascio P, Casarini S, Rognoni P, Touvier T, Marcatti M, Ciceri F, Mangiacavalli S, Corso A, Merlini G, Cenci S.

Blood. 2017 Apr 13;129(15):2132-2142. doi: 10.1182/blood-2016-08-730978. Epub 2017 Jan 27.

39.

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.

Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G.

Blood. 2017 Apr 13;129(15):2120-2123. doi: 10.1182/blood-2016-12-756528. Epub 2017 Jan 27.

40.

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

da Silva Filho MI, Försti A, Weinhold N, Meziane I, Campo C, Huhn S, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Morgan GJ, Houlston R, Goldschmidt H, Jauch A, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Hemminki K.

Leukemia. 2017 Aug;31(8):1735-1742. doi: 10.1038/leu.2016.387. Epub 2016 Dec 27.

PMID:
28025584
41.

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Sonneveld P, Dimopoulos MA.

Blood. 2017 Jan 26;129(4):456-459. doi: 10.1182/blood-2016-09-742411. Epub 2016 Nov 21.

42.

N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.

Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Hwa YL, Gonsalves WI, Zeldenrust SR, Kyle RA, Dispenzieri A.

Am J Hematol. 2016 Nov;91(11):1129-1134. doi: 10.1002/ajh.24532. Epub 2016 Aug 29.

43.

Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.

Milani P, Palladini G, Merlini G.

Scand J Clin Lab Invest Suppl. 2016;245:S113-8. doi: 10.1080/00365513.2016.1210337. Epub 2016 Jul 28. Review.

PMID:
27467897
44.

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.

Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL.

Leukemia. 2016 Oct;30(10):1979-1986. doi: 10.1038/leu.2016.191. Epub 2016 Jul 15. Review.

45.

In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.

Ami D, Lavatelli F, Rognoni P, Palladini G, Raimondi S, Giorgetti S, Monti L, Doglia SM, Natalello A, Merlini G.

Sci Rep. 2016 Jul 4;6:29096. doi: 10.1038/srep29096.

46.

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN.

Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.

PMID:
27143678
47.

European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.

Sachchithanantham S, Roussel M, Palladini G, Klersy C, Mahmood S, Venner CP, Gibbs S, Gillmore J, Lachmann H, Hawkins PN, Jaccard A, Merlini G, Wechalekar AD.

J Clin Oncol. 2016 Jun 10;34(17):2037-45. doi: 10.1200/JCO.2015.63.3123. Epub 2016 Apr 25.

PMID:
27114592
48.

What is new in diagnosis and management of light chain amyloidosis?

Palladini G, Merlini G.

Blood. 2016 Jul 14;128(2):159-68. doi: 10.1182/blood-2016-01-629790. Epub 2016 Apr 6. Review.

49.

Effects of a Bioavailable Arabinoxylan-enriched White Bread Flour on Postprandial Glucose Response in Normoglycemic Subjects.

Giulia Falchi A, Grecchi I, Muggia C, Palladini G, Perlini S.

J Diet Suppl. 2016 Nov;13(6):626-33. doi: 10.3109/19390211.2016.1156798. Epub 2016 Apr 6.

PMID:
27049812
50.

The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis.

Palladini G, Milani P, Foli A, Basset M, Russo F, Bosoni T, Pirolini L, Valentini V, Ferraro G, Lavatelli F, Barassi A, Albertini R, Merlini G.

Clin Chem Lab Med. 2016 Jun 1;54(6):939-45. doi: 10.1515/cclm-2015-0985.

PMID:
26943606

Supplemental Content

Loading ...
Support Center